Journal: Diagnostic Pathology

Article Title: Enhancer of zeste homologue 2 (EZH2) is a reliable immunohistochemical marker to differentiate malignant and benign hepatic tumors

doi: 10.1186/1746-1596-7-86

Figure Lengend Snippet: EZH2 staining

Article Snippet: The primary antibody was a mouse monoclonal anti-EZH2 (clone 11/EZH2) from BD Biosciences (San Jose CA, USA) (dilution 1:100).

Techniques: Expressing, Wilms Tumor Assay

Journal: Diagnostic Pathology

Article Title: Enhancer of zeste homologue 2 (EZH2) is a reliable immunohistochemical marker to differentiate malignant and benign hepatic tumors

doi: 10.1186/1746-1596-7-86

Figure Lengend Snippet: EZH2 staining in primary liver tumors. A/HCC, nuclear staining in tumor cells, the surrounding liver is negative; B/hepatocellular adenoma, there is no staining; C/CCC, note the unstained nuclei of the non tumorous bile duct in the center¸D/positively stained highly differentiated CCC (Klatskin tumour). Scale bar for the Figure 1:50 μm.

Article Snippet: The primary antibody was a mouse monoclonal anti-EZH2 (clone 11/EZH2) from BD Biosciences (San Jose CA, USA) (dilution 1:100).

Techniques: Staining

Journal: International Journal of Oral Science

Article Title: Single-cell transcriptomics reveals cell atlas and identifies cycling tumor cells responsible for recurrence in ameloblastoma

doi: 10.1038/s41368-024-00281-4

Figure Lengend Snippet: Targeting EZH2 inhibits proliferation and stemness in ameloblastoma cells. a Heatmap of the expression of stem cell-associated transcription factors in tumor cells. b Heatmap of the differentiated regulons of each epithelial cluster inferred by SCENIC. c Representative images of colony formation of sorted DiD low AM cells treated with EZH2 siRNAs or EZH2 inhibitors. d , e Quantification of colony numbers of sorted DiD low AM cells treated with EZH2 siRNAs or EZH2 inhibitors, ** P < 0.01 by one-way ANOVA. f Western blot images showing EZH2 expression of DiD low AM cells treated with EZH2 siRNAs. g Representative images showing spheres of sorted DiD low AM cells treated with two EZH2 inhibitors; scale bar, 100 μm. h , i Quantification of sphere number and diameter in sorted DiD low AM cells treated with or without EZH2 inhibitors, *** P < 0.001 by one-way ANOVA. j Representative images showing spheres of sorted DiD low AM cells treated with two different EZH2 siRNAs; scale bar, 100 μm. ( k, l ) Quantification of sphere number and diameter in sorted DiD low AM cells transfected with siRNA control or EZH2 siRNAs, *** P < 0.001 by one-way ANOVA

Article Snippet: The following primary antibodies were used: EZH2 (Cell Signaling Technology, Cat#5246 S; 1:2 000) and GAPDH (Proteintech, 10494-1-AP).

Techniques: Expressing, Western Blot, Transfection, Control

Journal: International Journal of Oral Science

Article Title: Single-cell transcriptomics reveals cell atlas and identifies cycling tumor cells responsible for recurrence in ameloblastoma

doi: 10.1038/s41368-024-00281-4

Figure Lengend Snippet: EZH2 is a novel therapeutic target for ameloblastoma. a KPNN analysis showing top 10 nodes with the most differential weights between primary and recurrent samples. b Representative images of organoids derived from T85 ameloblastoma samples; scale bar, 100 μm (left panel). Immunofluorescent staining showing the expression of PCK and ODAM in ameloblastoma organoids; scale bar, 50 μm (right panel). c , d Representative images and quantification of T85 and T88 ameloblastoma organoids treated with or without EPZ-6438, scale bar, 100 μm, *** P < 0.001 by Student’s t test. e , f Representative images and quantification of T91 and T93 ameloblastoma organoids treated with or without GSK126; scale bar, 100 μm, *** P < 0.001 by Student’s t test. g , h Immunofluorescent staining assay showed KI67 and PCK expression in organoids; scale bar, 50 μm (left panel). The percentage of KI67 expression in organoids with or without EZH2 inhibitors, * P < 0.05 and ** P < 0.01 by Student’s t test (right panel)

Article Snippet: The following primary antibodies were used: EZH2 (Cell Signaling Technology, Cat#5246 S; 1:2 000) and GAPDH (Proteintech, 10494-1-AP).

Techniques: Derivative Assay, Staining, Expressing

Journal: International Journal of Oral Science

Article Title: Single-cell transcriptomics reveals cell atlas and identifies cycling tumor cells responsible for recurrence in ameloblastoma

doi: 10.1038/s41368-024-00281-4

Figure Lengend Snippet: EZH2 expression is increased in recurrent AM and positively correlated with KI67 expression. a Violin plot showing the expression of EZH2 in the five clusters after splitting epithelial cells into primary and recurrent groups. b Representative images of EZH2 IHC staining in primary and recurrent ameloblastoma; scale bar, 100 μm (left panel). Quantification of EZH2 IHC staining in primary and recurrent ameloblastoma, *** P < 0.001 by Student’s t test (right panel). c Representative images of EZH2 IHC staining in unicystic and conventional ameloblastoma; scale bar, 100 μm (left panel). Quantification of EZH2 IHC staining in unicystic and conventional ameloblastoma, *** P < 0.001 by Student’s t test (right panel). d Representative images showing the same region of KI67 and EZH2 IHC staining in serial sections; scale bar, 100 μm (left panel). The correlation analysis between the expression of KI67 and EZH2 was assessed, *** P < 0.001 by Pearson (right panel)

Article Snippet: The following primary antibodies were used: EZH2 (Cell Signaling Technology, Cat#5246 S; 1:2 000) and GAPDH (Proteintech, 10494-1-AP).

Techniques: Expressing, Immunohistochemistry

Journal: Oncology Letters

Article Title: miR-26a inhibits invasion and metastasis of nasopharyngeal cancer by targeting EZH2

doi: 10.3892/ol.2013.1173

Figure Lengend Snippet: EZH2 was inversely correlated with miR-26a levels. (A) The expression levels of miR-26a and EZH2 in 5-8F cells transfected with LV-control and LV-miR-26a. ** P<0.01 compared with the control group. (B) The expression of EZH2 protein in cells transfected with LV-miR-26a was decreased compared with the control. (C) Immunohistochemistal staining of EZH2 in primary liver tumor tissues of NPC metastasis-bearing mice. The representative images are presented (magnification, ×100). EZH2, enhancer of zeste homolog 2; NPC, nasopharyngeal carcinoma.

Article Snippet: The membrane was incubated with a rabbit monoclonal antibody against human EZH2 (1:500 dilution, Cell Signaling Technology, Inc., Danvers, MA, USA) followed by HRP-labeled goat anti-mouse IgG (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) and detected by chemiluminescence.

Techniques: Expressing, Transfection, Control, Staining

Journal: Oncology Letters

Article Title: miR-26a inhibits invasion and metastasis of nasopharyngeal cancer by targeting EZH2

doi: 10.3892/ol.2013.1173

Figure Lengend Snippet: Immunohistochemical detection of EZH2 in primary tumors in the control and miR-26a groups.

Article Snippet: The membrane was incubated with a rabbit monoclonal antibody against human EZH2 (1:500 dilution, Cell Signaling Technology, Inc., Danvers, MA, USA) followed by HRP-labeled goat anti-mouse IgG (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) and detected by chemiluminescence.

Techniques: Immunohistochemical staining, Control

Journal: Scientific Reports

Article Title: ONECUT2 overexpression promotes RAS-driven lung adenocarcinoma progression

doi: 10.1038/s41598-019-56277-2

Figure Lengend Snippet: ONECUT2 modulates histone methylation through PRC2. ( A ) Western Blot of whole cell lysates from A549-ONECUT2 and A549-E.V. cells using indicated antibodies. The full-length blot is presented in Supplementary Fig. . ( B ) Heatmap of H3K27me3 and EZH2 log 2 fold change signal (A549-ONECUT2 versus ΔDBD) around centers of H3K27me3 loss regions. ( C ) Plot of average EZH2 log 2 fold change by ChIP-Seq (A549-ONECUT2 versus ΔDBD) around activating and repressive ONECUT2 peaks. ( D,E ) GSEA of ONECUT2-activated genes ( D ) and ONECUT2-upregulated genes ( E ) on gene list pre-ranked by log 2 FC after GSK126 treatment. ( F ) GSEA of GSK126 upregulation gene set on gene list pre-ranked based on log 2 FC (KPE versus KP) (Kras G12D/+ ; Trp53 fl/fl ; Eed fl/fl versus Kras G12D/+ ; Trp53 fl/fl ). ( G,H ) GSEA of ONECUT2-activated genes( G ) and ONECUT2-upregulated genes(H) on gene list pre-ranked by log 2 FC (KPE versus KE).

Article Snippet: Primary antibodies against EZH2 (5346 S, Cell Signaling), SUZ12 (3737 S, Cell Signaling), EED (05-1320, Millipore), HA (2367 S, Cell Signaling), GAPDH (G8795, Sigma) and α-tubulin (T5168, Sigma) were used in the study.

Techniques: Methylation, Western Blot, ChIP-sequencing

Journal: Oncology Letters

Article Title: Enhancer of zeste homolog 2 is involved in the proliferation of endometrial carcinoma

doi: 10.3892/ol.2014.2437

Figure Lengend Snippet: Expression of EZH2 in endometrial tissues. (A) EZH2 is overexpressed in the epithelium of endometrial cancer, atypical hyperplasia and complex hyperplasia compared with that in simple hyperplasia and normal endometrium. a, type 1 endometrioid endometrial cancer; b, type 2 endometrial cancer; c, atypical hyperplasia; d, complex hyperplasia; e, simple hyperplasia; f, proliferative endometrium. All images were captured at ×200 magnification using light microscopy and stained with hematoxylin. (B) Expression of EZH2 is higher in the epithelium of endometrial cancer, atypical hyperplasia and complex hyperplasia than in simple hyperplasia and normal endometrium. (C) Expression of EZH2 showed no difference in the stroma among groups. * P<0.05 and ** P<0.01. EZH2, enhancer of zeste homolog 2.

Article Snippet: The slides were then incubated with monoclonal antibodies against EZH2 (1:50; rabbit anti-human, -rat, -mouse and -monkey; Cell Signaling Technology, Inc.) at 4°C overnight.

Techniques: Expressing, Light Microscopy, Staining

Journal: Oncology Letters

Article Title: Enhancer of zeste homolog 2 is involved in the proliferation of endometrial carcinoma

doi: 10.3892/ol.2014.2437

Figure Lengend Snippet: The relationship between expression of EZH2 and clinicopathological characteristics in endometrial cancer.

Article Snippet: The slides were then incubated with monoclonal antibodies against EZH2 (1:50; rabbit anti-human, -rat, -mouse and -monkey; Cell Signaling Technology, Inc.) at 4°C overnight.

Techniques: Expressing

Journal: Oncology Letters

Article Title: Enhancer of zeste homolog 2 is involved in the proliferation of endometrial carcinoma

doi: 10.3892/ol.2014.2437

Figure Lengend Snippet: EZH2 knockdown inhibits the growth of endometrial cancer cells. (A) FAM-labeled scramble siRNA was transfected into Hec-1a and Ishikawa cells and the transfection efficiency was >90%; a, bright field of the cultured Hec-1a cells; and b, fluorescent field of the cultured Hec-1a cells following FAM-labeled siRNA transfection. (B) EZH2 knockdown was verified by western blot analysis. Growth curve of (C) Hec-1a and (D) Ishikawa cells after EZH2 siRNA transfection. Following transfection for 120 h, cell growth was significantly inhibited in both types of cells. * P<0.05 and ** P<0.01. EZH2, enhancer of zeste homolog; CCK-8, Cell Counting Kit-8.

Article Snippet: The slides were then incubated with monoclonal antibodies against EZH2 (1:50; rabbit anti-human, -rat, -mouse and -monkey; Cell Signaling Technology, Inc.) at 4°C overnight.

Techniques: Knockdown, Labeling, Transfection, Cell Culture, Western Blot, CCK-8 Assay, Cell Counting